Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism—A systematic review

Introduction Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanis...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2019-01, Vol.8 (1), p.238-245
Main Authors: Buch, Kristian, Gunmalm, Victoria, Andersson, Michael, Schwarz, Peter, Brøns, Charlotte
Format: Article
Language:English
Subjects:
Adjuvant therapy
Antineoplastic Agents - adverse effects
Aromatase
Aromatase Inhibitors - adverse effects
Body composition
Body weight gain
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Cancer Biology
Chemotherapy
Chemotherapy, Adjuvant
Female
Glucose
Glucose - metabolism
Humans
Insulin
Insulin - metabolism
Metabolism
Mushrooms
Review
weight gain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. Methods We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. Results A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Discussion Due to methodological limitations including short follow‐up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high‐risk of developing cardiometabolic disease after BC treatment. A systematic review on the changes in metabolism caused by adjuvant chemotherapy and/or aromatase inhibitors in the treatment of breast cancer (BC). We find a trend of increase in glucose and insulin. This could potentially lead to increased risk of cardiometabolic disease of BC treatment.
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.1911